Pathophysiologie der Hyperglykämie

  • Michael Berger
  • Viktor Jörgens

Zusammenfassung

Beim Gesunden wird der Blutglukosespiegel durch komplexe Regulationsmechanismen innerhalb enger Grenzen von etwa 60–140 mg/dl gehalten. Nicht nur im Ruhezustand, sondern besonders unter extremen Bedingungen wie bei anhaltendem Fasten, bei schweren Krankheiten oder bei erhöhtem Glukosebedarf, wie bei gesteigerter körperlicher Aktivität, bewirkt eine feine Abstimmung des Insulin-Glukagon-Verhältnisses an der Leber unter Kontrolle durch zentralnervöse, neurale, hormonelle und peptiderge Impulse die für das Überleben essentielle ausreichende Substratversorgung des Gehirns. Einer Neuroglukopenie mit drohender Bewußtlosigkeit kann nur vorgebeugt werden, solange der arterielle Blutglukosespiegel mindestens 50 mg/dl beträgt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Berger M (1996) To bridge science and patient care in diabetes. Diabetologia 39:749–757PubMedCrossRefGoogle Scholar
  2. Brownlee M (1991) Glycosyation products as toxic intermediates in diabetic complications. Ann Rev Med 42:159–166PubMedCrossRefGoogle Scholar
  3. Engermann R, Bloodworth JMB, Nelson S (1977) Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26:760–769CrossRefGoogle Scholar
  4. Hanssen KF, Dahl-Jörgensen K, Lauritzen T, Feldt-Rasmussen B, Brinkmann-Hansen O, Deckert T (1986) Diabetic control and microvascular complications: the near-normoglycaemic experience. Diabetologia 29:677–683PubMedCrossRefGoogle Scholar
  5. Liu QZ, Pettitt DJ, Hanson RL, Charles MA, Klein R, Bennett PH, Knowles WC (1993) Glycated hemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses. Diabetologia 36:428–432PubMedCrossRefGoogle Scholar
  6. Mühlhauser I (1989) UKPDS — Darstellung nach Evidence-based Medicine Kriterien. Diabetes & Stoffwechsel 7:267–273Google Scholar
  7. Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three major pathways of hyperglycaemic damage. Nature 404: 787–790PubMedCrossRefGoogle Scholar
  8. Pirart J (1978) Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1:168–188 (first part); 252–263 (second part)Google Scholar
  9. Sackett DL et al (2000) Evidence-based medicine. How to practice and teach EBM, 2nd edn. Churchill Livingstone, New York, USAGoogle Scholar
  10. Sawicki PT, Bender R, Berger M, Miihlhauser I (2000) Non-linear effects of blood pressure and glycosylated haemoglobin on progression of diabetic nephropathy. J Intern Med 247:131–138PubMedCrossRefGoogle Scholar
  11. The DCTT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRefGoogle Scholar
  12. The DCTT Research Group (1995): The relationship of glycemic exposure (HbAIc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968–983CrossRefGoogle Scholar
  13. The DCTT Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New Engl J Med 342:381–389CrossRefGoogle Scholar
  14. Trocha AK, Schmidtke C, Didjurgeit U et al. (1999) Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. J Hypertension 17:1497–1503CrossRefGoogle Scholar
  15. UGDP (1982) Effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Diabetes 31, suppl 5:1–81Google Scholar
  16. UKPDS 33 (1998) Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853Google Scholar
  17. UKPDS 38 (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit Med J 317:703–713Google Scholar
  18. Unger RH (1981) The milieu interieur and the islets of Langerhans. Diabetologia 20:1–11PubMedCrossRefGoogle Scholar
  19. Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46, suppl 2:19–25Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Michael Berger
    • 1
  • Viktor Jörgens
    • 1
  1. 1.Klinik für Stoffwechselkrankheiten und Ernährung WHO Collaborating Centre for DiabetesHeinrich-Heine-Universität DüsseldorfDüsseldorfDeutschland

Personalised recommendations